BioMarin Pharmaceutical Japan K.K.

Product Information : Genetically modified drug for mucopolysaccharidosis Type ⅣA

We provide information
about BioMarin’s products for healthcare professionals.

Home>To all healthcare professionals>Genetically modified drug for mucopolysaccharidosis Type ⅣA: Product Information

Product Information

Genetically modified drug for mucopolysaccharidosis Type ⅣA

VIMIZIM® ​​Intravenous Solution 5mg

VIMIZIM® ​​Intravenous Solution

Vimizim® (elosulfase alfa) is
an enzyme replacement therapy for the treatment of mucopolysaccharidosis IVA (Morquio A syndrome).

VIMIZIM® ​​Intravenous Solution
Generic Name Elosulfase alfa (genetically modified)
Indication Mucopolysaccharidosis IVA
Dosage and Administration Usually, intravenously infuse 2 mg of elosulfase alfa (genetically modified) per kg body weight at a time, once a week.

Materials on Our Products

For more information on diseases and products, please refer to the following PDF documents.

Package Insert Interview Form Explanation of
“Precautions for Use” Proper Use Guidelines Summary of
Product Information Materials
for patient explanation

Medical Reference

BioMarin Pharmaceutical Japan K.K. has established a medical information site " Medical Plus " For healthcare professionals .

Medical Plus
page top